Results 51 to 60 of about 268,751 (268)

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

Haematologica, 2018
The first-in-class, once-daily Bruton tyrosine kinase (BTK) inhibitor ibrutinib is one of the preferred standards of care for patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), which has a median overall survival (OS) of 4-5 years. We
S. Rule, M. Dreyling, A. Goy, G. Hess, R. Auer, B. Kahl, J. Hernández‐Rivas, K. Qi, S. Deshpande, Lori Parisi, Michael L. Wang   +10 more
semanticscholar   +1 more source

Targeting of the CD161 Inhibitory Receptor Enhances Bone‐Marrow‐Resident Memory CD8+ T‐Cell‐Mediated Immunity against Multiple Myeloma

Advanced Science, EarlyView.
CD161 is identified as a novel inhibitory receptor on bone marrow (BM)‐resident CD8⁺ T cells in multiple myeloma (MM). Through interaction with its ligand CLEC2D, CD161 impairs T‐cell function and promotes immune suppression. Blockade of CD161 restores tissue residency and cytotoxicity of CD8⁺ T cells and enhances chimeric antigen receptor T‐cell (CAR ...
Liwen Wang, Linzhi Xie, Yi Zhou, Shiming Tan, Yan Yu, Qin Zhang, Xuefeng Chen, Yuhan Yan, Ruiheng Luo, Han Xiao, Qian Cheng, Jian Zhang, Ying Li, Erhua Wang, Tiebin Jiang, Jing Liu, Xin Li   +16 more
wiley   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Haematologica, 2017
Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol
Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim   +11 more
doaj   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders

ChemMedChem, EarlyView.
A partial proteolysis targeting chimera (PROTAC) library bearing achiral phenyl dihydrouracil cereblon ligands is prepared. It is then applied to the rapid development of a full PROTAC library targeting Bruton's tyrosine kinase, which can be directly used for screening.
Chelsi M. Almodóvar‐Rivera, Ira Tandon, Ramesh Mudududdla, Paulina N. Esguerra, Kevin Lucio‐Acero, Weiping Tang   +5 more
wiley   +1 more source

Mantle cell lymphoma presented as enteric intussusception and involved gallbladder

Journal of Cancer Research and Practice, 2017
Intussusception caused by a lymphomatous mass is extremely rare in adults. To date, only four cases of mantle cell lymphoma have intussusception as a treatment sequelae or complication.
Chih-Ching Chin, Junping Shiau, Wei-Ciao Wu   +2 more
doaj   +1 more source

Recurrent mantle cell lymphoma in the uterine cervix: a case report

Journal of Medical Case Reports, 2020
Background Mantle cell lymphoma is one of several subtypes of non-Hodgkin lymphoma. Cervical relapse of non-Hodgkin lymphoma is a very rare condition that has a variable and nonspecific presentation and may resemble other neoplastic or inflammatory ...
Giusi Santangelo, Innocenza Palaia, Giorgia Perniola, Anna Di Pinto, Angela Musella, Federica Tomao, Margherita Fischetti, Carolina Sassu, Mariagrazia Piccioni, Violante Di Donato, Pierluigi Benedetti Panici   +10 more
doaj   +1 more source

Redefining the Skin Barrier: A Microbiome‐Integrated Multilayered Defense Model

Barrier Immunity, EarlyView.
ABSTRACT The skin constitutes a dynamic interface orchestrating a sophisticated multilayered defense system comprising physical, chemical, immune, and microbial barriers. This review synthesizes current understanding of the structural and functional integration of these barriers, emphasizing their synergistic interactions in maintaining cutaneous ...
Jingjing Xia, Mathias Hochgerner, Qingzhen Wei, Xian'ge Zhong, Jiucun Wang   +4 more
wiley   +1 more source

Synchronous pulmonary malignancies: atypical presentation of mantle cell lymphoma masking a lung malignancy

Rare Tumors, 2015
We present a case of a pleural space malignancy masked by an atypical presentation of mantle cell lymphoma. Our patient presented with a large pleural effusion and right sided pleural studding, initially attributed to a new diagnosis of mantle cell ...
Luke Masha, Andrey Zinchuk, Valia Boosalis   +2 more
doaj   +1 more source